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INTRODUCTION AND AIMS POPULATION AND METHODS
,
Renal dysfunction is a common complication of orthotopic liver
transplantation (OLT).
Long term use of cyclosporine (CyA) or tacrolimus (FK) can lead to
nephrotoxicity. The introduction of mycophenolate mofetil (MMF) and
sirolimus seems to improve renal function on these patients1-3.
This was a retrospective study of 626 patients receiving 708 OLT,
transplanted in our unit between September 1992 and March 2007.
Clinical data: age at transplantation, gender, weight, aetiology for hepatic
failure, presence of diabetes mellitus, hypertension, hepatitis B and C
infection, renal dysfunction pre transplant (RD pre) and ISS.
RESULTS
The aim of this study was to determine the incidence of acute and chronic
renal complications in OLT and its association with immunosuppression (ISS).
Laboratorial data: serum creatinine (Scr) values and/or glomerular filtration
rate (GFR), determined by Cockcroft-Gault equation, at the last observation
pre transplantation and at days 1, 7 and 21, month 6 and every year post
transplantation.
708 OLT recipients:
• Male gender 64%
M 44±12 6 150
200
250
Indications for transplantation
217
143
129
Present Immunosuppression 
• ean age: .  years
• Diabetes in 106 patients (17%); Hypertension in 117 patients (18.8%)
• Mean follow up time 3.6 years, 29% > to 5 years
• Mean transplant survival: 75% at 12 months and 69% at 3 years
• RD pre (GFRe < 60 ml/min or Scr >1.5 mg/dl): 133 recipients (21.6%)
• Retransplanted: 82 recipients
• Death: 152 recipients
0
50
100
FA
P
Al
co
ho
lic
 C
irr
ho
sis
Vir
al 
He
pa
titi
s
Fu
lm
ina
te 
He
pa
tit
is PB
C
Au
toi
mm
un
e C
irr
ho
sis
HC
Ca
rci
no
ma PS
C
A.
 Ph
all
oid
es
Cr
ipt
og
en
ic 
Ci
rrh
os
is
Ot
he
rs
36 35 28
14 9 8 8
0
5
10
15
20
25
30
35
40
45
50
Tacrolimus MMF Cyclosporine Azathioprine Sirolimus
Immunosuppression accomplished 
CyA
FK
Sirolimus
44.7% 46.4%
8.9%
r p
Cyclosporine 0.12 0.003
Azathioprine 0.14 0.001
MMF -0.16 <0.001
Tacrolimus -0.12 0.02
Sirolimus 0.16 <0.0001
CI 95% p R2
Cyclosporine 1.36 to 2.90 <0.001
0.20Sirolimus 0.05 to 0.31 0.008
MMF -0.22 to -0.07 0.001
GFRe < 45ml/min
Linear Regression
Spearman Correlation
MORTALITY
r p
Tacrolimus -0.12 0.006
MMF -0.09 0.02
Azathioprine 0.11 0.007
Spearman Correlation
CI 95% p
Tacrolimus -0.16 to -0.04 <0.001
Linear Regression
CONCLUSIONS
References:
1 - Créput C, Blandin F, Deroure B, et al. Lomg term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation 13: 1004-1010, 2007
2 - Reich DJ, Clavien PA, Hodge EE. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results Transplantation 80:18-25, 2005
3 - Fairbanks KD, Eustace JA, Pine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from calcineurin inhibitor to sirolimus Liver Transplant 9: 1079-1085, 2003
The use of FK and MMF seems to have better outcome in what concern to renal function, in contrast to CyA and 
Azathioprine.
Sirolimus may be important preventing further progression of renal failure.
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